Ascendis Pharma A/S (NASDAQ:ASND) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Monday, Zacks.com reports.

According to Zacks, “Ascendis Pharma A/S is a biopharmaceutical company. The company’s product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology, central nervous system disorders, infectious diseases and diabetes. Its technology includes TransCon which develop prodrug therapies. Ascendis Pharma A/S is based in Denmark. “

A number of other equities analysts have also commented on ASND. Cantor Fitzgerald reissued an “overweight” rating and set a $185.00 price target (up from $102.00) on shares of Ascendis Pharma A/S in a research note on Monday, March 4th. JPMorgan Chase & Co. increased their price target on Ascendis Pharma A/S from $85.00 to $145.00 and gave the company an “overweight” rating in a research note on Thursday, March 7th. Wedbush set a $217.00 price target on Ascendis Pharma A/S and gave the company an “outperform” rating in a research note on Thursday, March 7th. Evercore ISI started coverage on Ascendis Pharma A/S in a research note on Monday, March 25th. They set an “outperform” rating for the company. Finally, Credit Suisse Group dropped their price target on Ascendis Pharma A/S from $151.00 to $139.00 and set an “outperform” rating for the company in a research note on Friday, March 29th. One equities research analyst has rated the stock with a sell rating, nine have given a buy rating and two have assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $137.22.

Shares of Ascendis Pharma A/S stock opened at $118.80 on Monday. Ascendis Pharma A/S has a 12 month low of $53.21 and a 12 month high of $133.96. The company has a market cap of $5.19 billion, a P/E ratio of -31.76 and a beta of 0.77. The company has a debt-to-equity ratio of 0.02, a current ratio of 22.32 and a quick ratio of 22.32.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Wednesday, April 3rd. The biotechnology company reported ($0.87) EPS for the quarter, beating analysts’ consensus estimates of ($1.17) by $0.30. Ascendis Pharma A/S had a negative return on equity of 34.64% and a negative net margin of 901.89%. The company had revenue of $12.00 million during the quarter. Research analysts predict that Ascendis Pharma A/S will post -5.07 earnings per share for the current year.

Several large investors have recently bought and sold shares of the company. SG Americas Securities LLC lifted its stake in shares of Ascendis Pharma A/S by 12.6% in the 1st quarter. SG Americas Securities LLC now owns 2,088 shares of the biotechnology company’s stock valued at $246,000 after purchasing an additional 234 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Ascendis Pharma A/S by 1.1% in the 1st quarter. Geode Capital Management LLC now owns 31,073 shares of the biotechnology company’s stock valued at $3,657,000 after purchasing an additional 330 shares during the last quarter. Quantamental Technologies LLC bought a new stake in shares of Ascendis Pharma A/S in the 4th quarter valued at approximately $25,000. Citigroup Inc. bought a new stake in shares of Ascendis Pharma A/S in the 1st quarter valued at approximately $70,000. Finally, Emory University lifted its stake in shares of Ascendis Pharma A/S by 1.9% in the 4th quarter. Emory University now owns 39,217 shares of the biotechnology company’s stock valued at $2,457,000 after purchasing an additional 731 shares during the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Further Reading: Penny Stocks

Get a free copy of the Zacks research report on Ascendis Pharma A/S (ASND)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.